A 2023 review in CNS Drugs found that evidence for Prevagen is weak and largely from company-funded studies; calls for independent trials.
A 2023 review in CNS Drugs found that evidence for Prevagen is weak and largely from company-funded studies; calls for independent trials.
A comprehensive review examining the evidence behind popular over-the-counter memory supplements, evaluating their claimed benefits, safety profiles, and the quality of clinical research supporting their use.
Use the full description to understand the study design, methods, and the limits of the findings.
This review systematically evaluates the scientific evidence for commonly marketed memory supplements available without prescription. The analysis assesses ingredient efficacy, appropriate dosing, potential interactions, and gaps in current research to help consumers make informed decisions.
Open the original publication for the complete methods, outcomes, and source material.
The study is a systematic review of over-the-counter memory supplements, providing a high level of evidence through synthesis of existing research. While it offers valuable insights, the quality of evidence is contingent on the included studies, which may vary in methodological rigor. The study is relevant to seniors but does not exclusively focus on this age group.
| Category | Score | Rating |
|---|---|---|
| Study Design / Evidence Level | 6.0/10 | |
| Bias & Methods | 7.0/10 | |
| Statistical Integrity | 6.0/10 | |
| Transparency | 8.0/10 | |
| Conflict of Interest Disclosure | 9.0/10 | |
| Replication / External Validation | 5.0/10 | |
| Relevance to Seniors | 7.0/10 | |
| Journal Quality | 8.0/10 |
The systematic review approach is robust, but findings are limited by the quality and scope of the included studies. Further research focusing specifically on older adults would enhance relevance and applicability.
Build a personalized plan using research-backed studies, conditions, and treatments.